Progressing from Learning to Understanding: Future Path for ECMO Practice

Progressing from Learning to Understanding: Future Path for ECMO PracticeExtracorporeal membrane oxygenation (ECMO) has been established as a crucial life-sustaining system for individuals experiencing severe pulmonary or cardiopulmonary dysfunction, replacing heart and lung function to facilitate recovery by reducing myocardial stress and/or minimizing ventilator-induced lung injuries.Moreover, circulatory support ensures adequate cerebral blood flow, which may improve neurological outcomes 1 and patient survival.The support may also be extended for a durable solution such as transplantation or ventricular-assist device implantation, in cases of organ nonrecovery. 2Its utilization has expanded, encompassing patients with increasingly complex comorbidities, demonstrating its versatility in critical care. 3,4Moreover growing body of evidence supporting ECMO efficacy coupled with technological advancements, has established this modality in mainstream critical care practices.The current era has witnessed the refining patient selection criteria and optimizing management protocols along with the use of simpler and safer circuits associated with less complications.This has encouraged various categories of clinicians such as heart failure experts, critical care cardiologists, pediatricians and intensivists to perform the procedure safely at the bedside. 5he survival on VA-ECMO is not as good as VV-ECMO, moreover, individual requiring ECMO cardiopulmonary resuscitation (ECPR) have much worse outcome due to several factors.Recently VA-ECMO has emerged as a crucial support option for patients with acute cardiogenic shock (CS) secondary to acute coronary syndrome (ACS) with promising outcome though requiring significant resource utilization and morbidity, including higher bleeding risk requiring blood transfusions. 6Though the combination of VA-ECMO and intra-aortic balloon pump (IABP) has favorable outcome compared to VA-ECMO alone 7 , however adding Impella devices to VA-ECMO (ECPELLA) has shown higher rates of successful weaning from VA-ECMO and bridging to prolonged mechanical circulatory support options. 8While VA-ECMO offers a promising support strategy for ACS patients with refractory CS, several questions are still unanswered including appropriate patient selection, timing of initiation, and configuration of mechanical circulatory support for improving outcome.Categorization of patients prior to ECMO cannulation on the basis of Society for Cardiovascular Angiography and Interventions (SCAI) shock classification has emerged as a strong predictor of in-hospital mortality in patients receiving VA-ECMO for cardiogenic shock and higher mortality is expected with higher SCAI shock stage. 9This suggests that the SCAI classification can be used as a risk stratification tool to refine prognostication for ECMO recipients and guide future investigations to improve outcomes.Technical refinements such as double lumen VV cannulas to support a wider range of patient sizes, pumps with lower priming volumes, more efficient oxygenators, and changes in circuit configuration to reduce risk of hemolysis as well as minimizing flow turbulence have enhanced VV-ECMO capabilities. 10The timing of VV-ECMO initiation has been re-evaluated, with a trend towards earlier implementation in the course of respiratory failure and even use of "awake" ECMO as a first-line treatment alternative to invasive mechanical ventilation in spontaneously breathing patients with respiratory failure, has been advocated. 11This approach aims to avoid complications associated with sedation, intubation, and mechanical ventilation.Contradicting earlier beliefs, recent studies have shown that extended ECMO runs can have equivalent outcomes to shorter durations. 12nterestingly, though technological advancements have addressed several critical issues, anticoagulation management remains a significant challenge during ECMO support.While unfractionated heparin has been the standard anticoagulant, there is still limited international consensus on optimal anticoagulation protocols. 13,14The current researches are focusing on alternative anticoagulation strategies and advanced monitoring such as anti-Xa levels and point-of-care test instead of activated clotting time (ACT), which has shown promising outcome in reducing bleeding complications and improving outcome. 15rtificial intelligence (AI) has the potential to significantly enhance decision-making in ECMO management and patient monitoring by leveraging predictive analytics and decision support systems.AI-driven predictive analytics can analyze vast amounts of patient data, including vital signs, laboratory results, and imaging studies, to identify patterns and risk factors associated with ECMO outcomes. 16,17his capability enables early detection of potential complications and allows for proactive interventions, potentially improving patient outcomes.Machine learning algorithms can facilitate personalized treatment plans for ECMO patients by considering individual patient characteristics and response to therapy, leading to more tailored and effective interventions.Interestingly, while AI shows promise in enhancing ECMO management, it is crucial to note that traditional clinical decision-support systems may have limitations in surgical decision-making contexts.These systems often require time-consuming manual data management and may have suboptimal accuracy.To overcome these challenges, the integration of automated AI models fed by real-time electronic health record data and mobile device outputs could provide more timely and accurate decision support for ECMO management. 18n conclusion, ECMO technology continues to advance, with on-going research focusing on improving biocompatibility, reducing complications, and expanding its applications.Future developments may include the integration of artificial intelligence for optimizing ECMO management and patient outcomes.However, challenges remain, particularly in anticoagulation management, necessitating further research to establish evidence-based protocols and improve monitoring techniques.